| Hypertensive disease
Cleviprex vs Epaned
Side-by-side clinical, coverage, and cost comparison for hypertensive disease.Deep comparison between: Cleviprex vs Epaned with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEpaned has a higher rate of injection site reactions vs Cleviprex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Epaned but not Cleviprex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cleviprex
Epaned
At A Glance
IV infusion
Continuous infusion
Dihydropyridine CCB
Oral
Once or twice daily
ACE inhibitor
Indications
- Hypertensive disease
- Hypertensive disease
- Heart failure
- Ventricular Dysfunction, Left
Dosing
Hypertensive disease Initiate IV infusion at 1-2 mg/hour; double dose at 90-second intervals initially, then increase by less than doubling every 5-10 minutes as goal blood pressure is approached; maintenance 4-6 mg/hour; maximum 16 mg/hour (up to 32 mg/hour for severe hypertension); lipid load limit 1000 mL or an average of 21 mg/hour per 24 hours.
Hypertensive disease Adults: 5 mg once daily orally, titrated up to 40 mg daily; pediatric patients >1 month: 0.08 mg/kg (up to 5 mg) once daily; renal impairment (GFR <=30 mL/min) or dialysis: initial dose 2.5 mg daily.
Heart failure 2.5 mg twice daily orally, titrated up to 20 mg twice daily as tolerated; usually given in combination with diuretics and digitalis.
Ventricular Dysfunction, Left 2.5 mg twice daily orally, titrated up to 10 mg twice daily as tolerated.
Contraindications
- Allergy to soybeans, soy products, eggs, or egg products
- Defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis accompanied by hyperlipidemia
- Severe aortic stenosis
- History of angioedema or hypersensitivity related to previous ACE inhibitor treatment
- Hereditary or idiopathic angioedema
- Co-administration of aliskiren in patients with diabetes
- Combination with a neprilysin inhibitor (e.g., sacubitril), or within 36 hours of switching to or from sacubitril/valsartan
Adverse Reactions
Most common Headache, nausea, vomiting, acute renal failure, atrial fibrillation
Serious Myocardial infarction, cardiac arrest, syncope, dyspnea
Postmarketing Increased blood triglycerides, ileus, hypersensitivity, hypotension, nausea, decreased oxygen saturation, reflex tachycardia
Most common (>1%) Fatigue, orthostatic effects, asthenia, cough, rash; in heart failure patients: hypotension, dizziness.
Serious Angioedema, hypotension, hepatic failure, renal impairment, hyperkalemia, cardiac arrest, myocardial infarction, cerebrovascular accident, neutropenia, thrombocytopenia, bone marrow depression.
Postmarketing Pancreatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, pemphigus, eosinophilic pneumonitis, pulmonary infiltrates, gynecomastia.
Pharmacology
Clevidipine is a dihydropyridine L-type calcium channel blocker that lowers blood pressure by inhibiting calcium influx in arterial smooth muscle, reducing systemic vascular resistance without affecting venous preload or cardiac filling pressure.
ACE inhibitor; enalapril is hydrolyzed to enalaprilat, which inhibits angiotensin-converting enzyme, suppressing the renin-angiotensin-aldosterone system and thereby reducing plasma angiotensin II, vasopressor activity, and aldosterone secretion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cleviprex
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Epaned
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Cleviprex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Epaned
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cleviprex
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Epaned
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cleviprex.
No savings programs available for Epaned.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CleviprexView full Cleviprex profile
EpanedView full Epaned profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.